SUPPLEMENTARY MATERIAL

The Natural Product NI-07, Is Effective Against Breast Cancer Cells While Showing No Cytotoxicity to Normal Cells

Lauren S. Gollahon, Yunseong Jeong, Velvetlee Finckbone, Kyungwoo Lee and Jong-Sang Park



Suppl. Fig. (1). Results of HCC1419 breast cancer cell viability during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 or Taxol™. Fresh medium was added on day 3 LC50. **A**) Cell viability during LC50 determined by Trypan Blue exclusion performed simultaneously with cell counts. **B**) Cell viability during Recovery determined by Trypan Blue exclusion performed simultaneously with cell counts.



Suppl. Fig. (2). Results of MCF7 breast cancer cell viability during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 or Taxol™. Fresh medium was added on day 3 LC50. **A**) Cell viability during LC50 determined by Trypan Blue exclusion performed simultaneously with cell counts. **B**) Cell viability during Recovery determined by Trypan Blue exclusion performed simultaneously with cell counts.



Suppl. Fig. (3). Results of MDA-MB-468 breast cancer cell viability during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 or Taxol™. Fresh medium was added on day 3 LC50. **A**) Cell viability during LC50 determined by Trypan Blue exclusion performed simultaneously with cell counts. **B**) Cell viability during Recovery determined by Trypan Blue exclusion performed simultaneously with cell counts.



Suppl. Fig. (4). Results of SKBR3 breast cancer cell viability during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 or Taxol™. Fresh medium was added on day 3 LC50. **A**) Cell viability during LC50 determined by Trypan Blue exclusion performed simultaneously with cell counts. **B**) Cell viability during Recovery determined by Trypan Blue exclusion performed simultaneously with cell counts.



Suppl. Fig. (5). Results of HME cell viability and drug cytotoxicity during treatment with NI-07. Cells were plated and 24 - 48 h later, treated with either NI-07 (7 days) or Taxol™ (24 h). Fresh medium was added on day 3 LC50. **A**) Cell viability during LC50 was determined by Trypan Blue exclusion performed simultaneously with cell counts. **B**) Cell viability during Recovery was determined by Trypan Blue exclusion performed simultaneously with cell counts. **C**, **D**) Cytotoxicity of NI-07 and Taxol™ on HME cells during LC50 and Recovery, respectively. The cytotoxicity of NI-07 and Taxol™ was determined by XTT analysis.



Suppl. Fig. (6). Results of fibroblast cell viability and drug cytotoxicity during treatment with NI-07. CCDsk cells were plated and 24 - 48 h later, treated with either NI-07 (7 days) or Taxol™ (24 h). Fresh medium was added on day 3 LC50. **A**) Cell viability during LC50 was determined by Trypan Blue exclusion performed simultaneously with cell counts. **B**) Cell viability during Recovery was determined by Trypan Blue exclusion performed simultaneously with cell counts. **C**, **D**) Cytotoxicity of NI-07 and Taxol™ on HME cells during LC50 and Recovery, respectively. The cytotoxicity of NI-07 and Taxol™ was determined by XTT analysis.